流感病毒和 SARS-CoV-2 疫苗。
Influenza Virus and SARS-CoV-2 Vaccines.
机构信息
Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC.
Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC.
出版信息
J Immunol. 2021 Jun 1;206(11):2509-2520. doi: 10.4049/jimmunol.2001287. Epub 2021 May 21.
Abstract
Seasonal influenza and the current COVID-19 pandemic represent looming global health challenges. Efficacious and safe vaccines remain the frontline tools for mitigating both influenza virus and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-induced diseases. This review will discuss the existing strategies for influenza vaccines and how these strategies have informed SARS-CoV-2 vaccines. It will also discuss new vaccine platforms and potential challenges for both viruses.
摘要
季节性流感和当前的 COVID-19 大流行是全球卫生面临的严峻挑战。有效的、安全的疫苗仍然是缓解流感病毒和严重急性呼吸综合征冠状病毒 2 型（SARS-CoV-2）引起的疾病的一线工具。本文将讨论现有的流感疫苗策略，以及这些策略如何为 SARS-CoV-2 疫苗提供信息。还将讨论两种病毒的新疫苗平台和潜在挑战。
相似文献
1
Influenza Virus and SARS-CoV-2 Vaccines.流感病毒和 SARS-CoV-2 疫苗。
J Immunol. 2021 Jun 1;206(11):2509-2520. doi: 10.4049/jimmunol.2001287. Epub 2021 May 21.
2
A Virion-Based Combination Vaccine Protects against Influenza and SARS-CoV-2 Disease in Mice.基于病毒粒子的联合疫苗可预防小鼠流感和 SARS-CoV-2 疾病。
J Virol. 2022 Aug 10;96(15):e0068922. doi: 10.1128/jvi.00689-22. Epub 2022 Jul 12.
3
Lessons Relearned? H1N1, COVID-19, and Vaccination Planning.吸取的教训？甲型H1N1流感、新冠疫情与疫苗接种规划。
J Public Health Manag Pract. 2021 Jan/Feb;27 Suppl 1, COVID-19 and Public Health: Looking Back, Moving Forward:S106-S110. doi: 10.1097/PHH.0000000000001289.
4
[Vaccinations in pulmonary diseases - part 1: Covid and influenza].[肺部疾病中的疫苗接种 - 第1部分：新冠与流感]
Dtsch Med Wochenschr. 2024 Aug;149(17):1045-1049. doi: 10.1055/a-2115-0404. Epub 2024 Aug 15.
5
Meeting Report From "Correlates of Protection for Next Generation Influenza Vaccines: Lessons Learned From the COVID-19 Pandemic".会议报告：“下一代流感疫苗的保护相关因素：从 COVID-19 大流行中吸取的经验教训”。
Influenza Other Respir Viruses. 2024 Oct;18(10):e13314. doi: 10.1111/irv.13314.
6
The COVID-19 and Influenza "Twindemic": Barriers to Influenza Vaccination and Potential Acceptance of SARS-CoV2 Vaccination in African Americans.COVID-19 和流感“双重流行”：非裔美国人接种流感疫苗的障碍和对 SARS-CoV2 疫苗接种的潜在接受程度。
J Natl Med Assoc. 2020 Dec;112(6):681-687. doi: 10.1016/j.jnma.2020.11.001. Epub 2020 Dec 1.
7
Potential Therapeutic Targets and Vaccine Development for SARS-CoV-2/COVID-19 Pandemic Management: A Review on the Recent Update.SARS-CoV-2/COVID-19 大流行管理的潜在治疗靶点和疫苗开发：近期进展综述。
Front Immunol. 2021 Jun 30;12:658519. doi: 10.3389/fimmu.2021.658519. eCollection 2021.
8
Influenza immunization and COVID-19.流感疫苗接种与新型冠状病毒肺炎
Vaccine. 2020 Sep 3;38(39):6078-6079. doi: 10.1016/j.vaccine.2020.07.058. Epub 2020 Jul 29.
9
A Single Vaccine Protects against SARS-CoV-2 and Influenza Virus in Mice.一种疫苗可同时预防小鼠感染 SARS-CoV-2 和流感病毒。
J Virol. 2022 Feb 23;96(4):e0157821. doi: 10.1128/JVI.01578-21. Epub 2021 Dec 15.
10
Coronavirus vaccine development: from SARS and MERS to COVID-19.冠状病毒疫苗的研发：从 SARS 和 MERS 到 COVID-19。
J Biomed Sci. 2020 Dec 20;27(1):104. doi: 10.1186/s12929-020-00695-2.
引用本文的文献
1
A Case of Triple Respiratory Coinfection: COVID-19, Enterovirus, and Parainfluenza.一例三重呼吸道合并感染病例：新型冠状病毒肺炎、肠道病毒和副流感病毒
Cureus. 2024 Nov 3;16(11):e72949. doi: 10.7759/cureus.72949. eCollection 2024 Nov.
2
From Detection to Protection: Antibodies and Their Crucial Role in Diagnosing and Combatting SARS-CoV-2.从检测到防护：抗体及其在诊断和对抗新冠病毒中的关键作用。
Vaccines (Basel). 2024 Apr 25;12(5):459. doi: 10.3390/vaccines12050459.
3
Eliciting a single amino acid change by vaccination generates antibody protection against group 1 and group 2 influenza A viruses.通过接种疫苗诱发出单个氨基酸改变，可产生针对甲型流感病毒 1 型和 2 型的抗体保护。
Immunity. 2024 May 14;57(5):1141-1159.e11. doi: 10.1016/j.immuni.2024.03.022. Epub 2024 Apr 25.
4
Pandemic H1N1 influenza virus triggers a strong T helper cell response in human nasopharynx-associated lymphoid tissues.大流行性H1N1流感病毒在人类鼻咽相关淋巴组织中引发强烈的辅助性T细胞反应。
Saudi J Biol Sci. 2024 Mar;31(3):103941. doi: 10.1016/j.sjbs.2024.103941. Epub 2024 Jan 28.
5
Advances in Next-Generation Coronavirus Vaccines in Response to Future Virus Evolution.应对未来病毒进化的新一代冠状病毒疫苗进展
Vaccines (Basel). 2022 Nov 29;10(12):2035. doi: 10.3390/vaccines10122035.
6
Influenza Virus-like Particle-Based Hybrid Vaccine Containing RBD Induces Immunity against Influenza and SARS-CoV-2 Viruses.含受体结合域的流感病毒样颗粒杂交疫苗可诱导针对流感病毒和新冠病毒的免疫反应。
Vaccines (Basel). 2022 Jun 14;10(6):944. doi: 10.3390/vaccines10060944.
7
Molecular Modeling and Preliminary Clinical Data Suggesting Antiviral Activity for Chlorpheniramine (Chlorphenamine) Against COVID-19.分子建模与初步临床数据表明氯苯那敏对新冠病毒具有抗病毒活性。
Cureus. 2022 Jan 6;14(1):e20980. doi: 10.7759/cureus.20980. eCollection 2022 Jan.
8
Strategies for fighting pandemic virus infections: Integration of virology and drug delivery.抗击病毒感染的策略：病毒学与药物输送的融合。
J Control Release. 2022 Mar;343:361-378. doi: 10.1016/j.jconrel.2022.01.046. Epub 2022 Feb 3.
9
Hyperactivated RAGE in Comorbidities as a Risk Factor for Severe COVID-19-The Role of RAGE-RAS Crosstalk.高活性 RAGE 在合并症中作为 COVID-19 重症的风险因素- RAGE-RAS 串扰的作用。
Biomolecules. 2021 Jun 12;11(6):876. doi: 10.3390/biom11060876.
本文引用的文献
1
Attenuated activation of pulmonary immune cells in mRNA-1273-vaccinated hamsters after SARS-CoV-2 infection.感染 SARS-CoV-2 后，mRNA-1273 疫苗接种的仓鼠肺部免疫细胞的激活减弱。
J Clin Invest. 2021 Oct 15;131(20). doi: 10.1172/JCI148036.
2
Immunogenic potential of DNA vaccine candidate, ZyCoV-D against SARS-CoV-2 in animal models.DNA 疫苗候选物 ZyCoV-D 对动物模型中 SARS-CoV-2 的免疫原性。
Vaccine. 2021 Jul 5;39(30):4108-4116. doi: 10.1016/j.vaccine.2021.05.098. Epub 2021 Jun 1.
3
COVID-19, a worldwide public health emergency.COVID-19，一场全球性的公共卫生紧急事件。
Rev Clin Esp (Barc). 2021 Jan;221(1):55-61. doi: 10.1016/j.rceng.2020.03.001. Epub 2020 Apr 21.
4
Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study.《新型冠状病毒 SARS-CoV-2 BNT162b1 mRNA 疫苗在中国年轻和老年成年人中的安全性和免疫原性：一项随机、安慰剂对照、双盲的 1 期研究》。
Nat Med. 2021 Jun;27(6):1062-1070. doi: 10.1038/s41591-021-01330-9. Epub 2021 Apr 22.
5
Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine.接种 BNT162b2 疫苗后 SARS-CoV-2 病毒载量下降的初步报告。
Nat Med. 2021 May;27(5):790-792. doi: 10.1038/s41591-021-01316-7. Epub 2021 Mar 29.
6
Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials.一种基于重组串联重复二聚体 RBD 的蛋白亚单位疫苗（ZF2001）在成年人中的安全性和免疫原性：两项随机、双盲、安慰剂对照、1 期和 2 期临床试验。
Lancet Infect Dis. 2021 Aug;21(8):1107-1119. doi: 10.1016/S1473-3099(21)00127-4. Epub 2021 Mar 24.
7
Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine.mRNA-1273疫苗引发的血清中和活性。
N Engl J Med. 2021 Apr 15;384(15):1468-1470. doi: 10.1056/NEJMc2102179. Epub 2021 Mar 17.
8
Assessment of the Inclusion of Racial/Ethnic Minority, Female, and Older Individuals in Vaccine Clinical Trials.评估种族/少数民族、女性和老年人在疫苗临床试验中的纳入情况。
JAMA Netw Open. 2021 Feb 1;4(2):e2037640. doi: 10.1001/jamanetworkopen.2020.37640.
9
A rapid review of recent advances in diagnosis, treatment and vaccination for COVID-19.对新型冠状病毒肺炎（COVID-19）诊断、治疗及疫苗接种方面近期进展的快速综述。
AIMS Public Health. 2021 Feb 1;8(1):137-153. doi: 10.3934/publichealth.2021011. eCollection 2021.
10
mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants.mRNA 疫苗诱导的针对 SARS-CoV-2 和循环变异株的抗体。
Nature. 2021 Apr;592(7855):616-622. doi: 10.1038/s41586-021-03324-6. Epub 2021 Feb 10.
Zotero 插件